284 related articles for article (PubMed ID: 19937937)
1. Nephrogenic systemic fibrosis in liver disease: a systematic review.
Mazhar SM; Shiehmorteza M; Kohl CA; Middleton MS; Sirlin CB
J Magn Reson Imaging; 2009 Dec; 30(6):1313-22. PubMed ID: 19937937
[TBL] [Abstract][Full Text] [Related]
2. High-dose gadodiamide for catheter angiography and CT in patients with varying degrees of renal insufficiency: Prevalence of subsequent nephrogenic systemic fibrosis and decline in renal function.
Bridges MD; St Amant BS; McNeil RB; Cernigliaro JG; Dwyer JP; Fitzpatrick PM
AJR Am J Roentgenol; 2009 Jun; 192(6):1538-43. PubMed ID: 19457816
[TBL] [Abstract][Full Text] [Related]
3. Incidence of Nephrogenic Systemic Fibrosis Using Gadobenate Dimeglumine in 1423 Patients With Renal Insufficiency Compared With Gadodiamide.
Bruce R; Wentland AL; Haemel AK; Garrett RW; Sadowski DR; Djamali A; Sadowski EA
Invest Radiol; 2016 Nov; 51(11):701-705. PubMed ID: 26885631
[TBL] [Abstract][Full Text] [Related]
4. Nephrogenic systemic fibrosis: risk factors suggested from Japanese published cases.
Tsushima Y; Kanal E; Thomsen HS
Br J Radiol; 2010 Jul; 83(991):590-5. PubMed ID: 20413447
[TBL] [Abstract][Full Text] [Related]
5. Prevalence of nephrogenic systemic fibrosis in renal insufficiency patients: results of the FINEST study.
Janus N; Launay-Vacher V; Karie S; Clement O; Ledneva E; Frances C; Choukroun G; Deray G
Eur J Radiol; 2010 Feb; 73(2):357-9. PubMed ID: 19128909
[TBL] [Abstract][Full Text] [Related]
6. Nephrogenic systemic fibrosis: incidence, associations, and effect of risk factor assessment--report of 33 cases.
Perez-Rodriguez J; Lai S; Ehst BD; Fine DM; Bluemke DA
Radiology; 2009 Feb; 250(2):371-7. PubMed ID: 19188312
[TBL] [Abstract][Full Text] [Related]
7. Incidence of nephrogenic systemic fibrosis after adoption of restrictive gadolinium-based contrast agent guidelines.
Wang Y; Alkasab TK; Narin O; Nazarian RM; Kaewlai R; Kay J; Abujudeh HH
Radiology; 2011 Jul; 260(1):105-11. PubMed ID: 21586680
[TBL] [Abstract][Full Text] [Related]
8. Risk factors for NSF: a literature review.
Prince MR; Zhang HL; Roditi GH; Leiner T; Kucharczyk W
J Magn Reson Imaging; 2009 Dec; 30(6):1298-308. PubMed ID: 19937930
[TBL] [Abstract][Full Text] [Related]
9. Risk of nephrogenic systemic fibrosis is low in patients with chronic liver disease exposed to gadolinium-based contrast agents.
Smorodinsky E; Ansdell DS; Foster ZW; Mazhar SM; Cruite I; Wolfson T; Sugay SB; Iussich G; Shiehmorteza M; Kono Y; Kuo A; Sirlin CB
J Magn Reson Imaging; 2015 May; 41(5):1259-67. PubMed ID: 24811860
[TBL] [Abstract][Full Text] [Related]
10. Nephrogenic systemic fibrosis: center case review.
Lauenstein TC; Salman K; Morreira R; Tata S; Tudorascu D; Baramidze G; Singh-Parker S; Martin DR
J Magn Reson Imaging; 2007 Nov; 26(5):1198-203. PubMed ID: 17969162
[TBL] [Abstract][Full Text] [Related]
11. Incidence of nephrogenic systemic fibrosis at two large medical centers.
Prince MR; Zhang H; Morris M; MacGregor JL; Grossman ME; Silberzweig J; DeLapaz RL; Lee HJ; Magro CM; Valeri AM
Radiology; 2008 Sep; 248(3):807-16. PubMed ID: 18710976
[TBL] [Abstract][Full Text] [Related]
12. Gadolinium-based contrast exposure, nephrogenic systemic fibrosis, and gadolinium detection in tissue.
Wiginton CD; Kelly B; Oto A; Jesse M; Aristimuno P; Ernst R; Chaljub G
AJR Am J Roentgenol; 2008 Apr; 190(4):1060-8. PubMed ID: 18356456
[TBL] [Abstract][Full Text] [Related]
13. Nephrogenic systemic fibrosis: review of 370 biopsy-confirmed cases.
Zou Z; Zhang HL; Roditi GH; Leiner T; Kucharczyk W; Prince MR
JACC Cardiovasc Imaging; 2011 Nov; 4(11):1206-16. PubMed ID: 22093272
[TBL] [Abstract][Full Text] [Related]
14. A Systematic Review of 639 Patients with Biopsy-confirmed Nephrogenic Systemic Fibrosis.
Attari H; Cao Y; Elmholdt TR; Zhao Y; Prince MR
Radiology; 2019 Aug; 292(2):376-386. PubMed ID: 31264946
[TBL] [Abstract][Full Text] [Related]
15. Nephrogenic systemic fibrosis is found only among gadolinium-exposed patients with renal insufficiency: a case-control study from Denmark.
Elmholdt TR; Pedersen M; Jørgensen B; Søndergaard K; Jensen JD; Ramsing M; Olesen AB
Br J Dermatol; 2011 Oct; 165(4):828-36. PubMed ID: 21692765
[TBL] [Abstract][Full Text] [Related]
16. Risk of Nephrogenic Systemic Fibrosis in Patients With Stage 4 or 5 Chronic Kidney Disease Receiving a Group II Gadolinium-Based Contrast Agent: A Systematic Review and Meta-analysis.
Woolen SA; Shankar PR; Gagnier JJ; MacEachern MP; Singer L; Davenport MS
JAMA Intern Med; 2020 Feb; 180(2):223-230. PubMed ID: 31816007
[TBL] [Abstract][Full Text] [Related]
17. Gadobenate Dimeglumine Administration and Nephrogenic Systemic Fibrosis: Is There a Real Risk in Patients with Impaired Renal Function?
Nandwana SB; Moreno CC; Osipow MT; Sekhar A; Cox KL
Radiology; 2015 Sep; 276(3):741-7. PubMed ID: 25875973
[TBL] [Abstract][Full Text] [Related]
18. Gadodiamide-associated nephrogenic systemic fibrosis: why radiologists should be concerned.
Broome DR; Girguis MS; Baron PW; Cottrell AC; Kjellin I; Kirk GA
AJR Am J Roentgenol; 2007 Feb; 188(2):586-92. PubMed ID: 17242272
[TBL] [Abstract][Full Text] [Related]
19. Large sample of nephrogenic systemic fibrosis cases from a single institution.
Lee CU; Wood CM; Hesley GK; Leung N; Bridges MD; Lund JT; Lee PU; Pittelkow MR
Arch Dermatol; 2009 Oct; 145(10):1095-102. PubMed ID: 19841395
[TBL] [Abstract][Full Text] [Related]
20. Retrospective assessment of prevalence of nephrogenic systemic fibrosis (NSF) after implementation of a new guideline for the use of gadobenate dimeglumine as a sole contrast agent for magnetic resonance examination in renally impaired patients.
Abujudeh HH; Rolls H; Kaewlai R; Agarwal S; Gebreananya ZA; Saini S; Schaefer PW; Kay J
J Magn Reson Imaging; 2009 Dec; 30(6):1335-40. PubMed ID: 19937927
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
